0000899243-22-031062.txt : 20220914
0000899243-22-031062.hdr.sgml : 20220914
20220914171013
ACCESSION NUMBER: 0000899243-22-031062
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220912
FILED AS OF DATE: 20220914
DATE AS OF CHANGE: 20220914
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PATRICK DEVAL L
CENTRAL INDEX KEY: 0001053466
STANDARD INDUSTRIAL CLASSIFICATION: AIR TRANSPORTATION, SCHEDULED [4512]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39311
FILM NUMBER: 221243666
MAIL ADDRESS:
STREET 1: BAIN CAPITAL, LLC
STREET 2: 200 CLARENDON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cerevel Therapeutics Holdings, Inc.
CENTRAL INDEX KEY: 0001805387
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 222 JACOBS STREET
STREET 2: SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 844-304-2048
MAIL ADDRESS:
STREET 1: 222 JACOBS STREET
STREET 2: SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
FORMER COMPANY:
FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp II
DATE OF NAME CHANGE: 20200303
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-09-12
0
0001805387
Cerevel Therapeutics Holdings, Inc.
CERE
0001053466
PATRICK DEVAL L
C/O CEREVEL THERAPEUTICS HOLDINGS, INC.
222 JACOBS STREET, SUITE 200
CAMBRIDGE
MA
02141
1
0
0
0
Common Stock
2022-09-12
4
M
0
47705
12.62
A
47705
D
Common Stock
2022-09-12
4
S
0
47705
30.7813
D
0
D
Stock Option (Right to Buy)
12.62
2022-09-12
4
M
0
47705
0.00
D
2031-02-01
Common Stock
47705
42685
D
These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 12, 2022 adopted by the Reporting Person.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.29 - $31.11. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
This option shall vest in thirty-six (36) equal monthly installments over three (3) years, with the first installment vested on February 1, 2021.
/s/ Mark Bodenrader, as Attorney-in-Fact
2022-09-14